Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun;67(6):454-63.
doi: 10.1007/s00105-016-3806-2.

[Psoriasis in special localizations]

[Article in German]
Affiliations
Review

[Psoriasis in special localizations]

[Article in German]
A Schmieder et al. Hautarzt. 2016 Jun.

Abstract

A large proportion of patients with plaque psoriasis suffer from psoriatic lesions of the scalp, nails, and intertrigines. These locations can also be soley or predominantly affected. Scalp psoriasis, nail psoriasis, and inverse psoriasis are often perceived as particularly stigmatizing. Involvement of these parts of the body is associated with an increased risk of psoriatic arthritis. Location-specific features must be considered when choosing treatment. Evidence for topical therapy of scalp psoriasis with steroids and combinations of steroids and vitamin D analogues is high. These agents are regarded as safe and effective treatments of first choice. Efficacy of TNF antagonists and apremilast is well documented for refractory scalp psoriasis. Nail psoriasis often responds insufficiently to topical therapy. Several effective systemic medications including methotrexate and TNF antagonists are available for treatment of severe forms. Controlled trials for treatment of inverse psoriasis are scarce. Topical steroids, vitamin D analogues, dithranol, and off-label calcineurin inhibitors are used in clinical practice. This review provides a survey on the clinical presentation and current evidence for treatment of psoriasis in challenging locations.

Keywords: Biologicals; Intertrigo; Nail; Scalp; Topical steroids.

PubMed Disclaimer

References

    1. J Am Acad Dermatol. 2004 Nov;51(5):723-30 - PubMed
    1. Br J Dermatol. 2013 May;168(5):1080-7 - PubMed
    1. Actas Dermosifiliogr. 2014 Dec;105(10 ):923-34 - PubMed
    1. J Eur Acad Dermatol Venereol. 2011 Sep;25(9):1080-4 - PubMed
    1. Acta Derm Venereol. 2002;82(2):140 - PubMed

MeSH terms

LinkOut - more resources